Boyle, J.P., Thompson, T.J., Gregg, E.W., Barker, L.E. & Williamson, D.F. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul. Health Metr. 8, 29 (2010).
US Center for Disease Control and Prevention. National diabetes statistics report, 2014. Diabetes Public Health Resource http://www.cdc.gov/diabetes/pubs/statsreport14.htm (2014).
Qaseem, A., Humphrey, L.L., Sweet, D.E., Starkey, M. & Shekelle, P. Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 156, 218–231 (2012).
Nathan, D.M., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32, 193–203 (2009).
Kahn, S.E., Hull, R.L. & Utzschneider, K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444, 840–846 (2006).
Muoio, D.M. & Newgard, C.B. Obesity-related derangements in metabolic regulation. Annu. Rev. Biochem. 75, 367–401 (2006).
Randle, P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14, 263–283 (1998).
Samuel, V.T., Petersen, K.F. & Shulman, G.I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267–2277 (2010).
An, J. et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat. Med. 10, 268–274 (2004).
Chavez, J.A. & Summers, S.A. A ceramide-centric view of insulin resistance. Cell Metab. 15, 585–594 (2012).
Griffin, M.E. et al. Free fatty acid–induced insulin resistance is associated with activation of protein kinase Cθ and alterations in the insulin signaling cascade. Diabetes 48, 1270–1274 (1999).
Holland, W.L. et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat–, and obesity-induced insulin resistance. Cell Metab. 5, 167–179 (2007).
Samuel, V.T. & Shulman, G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852–871 (2012).
Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432 (1994).
Pelleymounter, M.A. et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269, 540–543 (1995).
Uysal, K.T., Wiesbrock, S.M., Marino, M.W. & Hotamisligil, G.S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389, 610–614 (1997).
Yamauchi, T. et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941–946 (2001).
Steppan, C.M. et al. The hormone resistin links obesity to diabetes. Nature 409, 307–312 (2001).
Yuan, M. et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293, 1673–1677 (2001).
Yang, Q. et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436, 356–362 (2005).
Henry, R.R., Wallace, P. & Olefsky, J.M. Effects of weight loss on mechanisms of hyperglycemia in obese non–insulin-dependent diabetes mellitus. Diabetes 35, 990–998 (1986).
Kantartzis, K. et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58, 1281–1288 (2009).
Perseghin, G. et al. Increased glucose transport-phosphorylation and muscle glycogen synthesis after exercise training in insulin-resistant subjects. N. Engl. J. Med. 335, 1357–1362 (1996).
Petersen, K.F. et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54, 603–608 (2005).
Terada, H. Uncouplers of oxidative phosphorylation. Environ. Health Perspect. 87, 213–218 (1990).
Nedergaard, J., Ricquier, D. & Kozak, L.P. Uncoupling proteins: current status and therapeutic prospects. EMBO Rep. 6, 917–921 (2005).
Si, Y., Shi, H. & Lee, K. Metabolic flux analysis of mitochondrial uncoupling in 3T3–L1 adipocytes. PLoS ONE 4, e7000 (2009).
Tseng, Y.H., Cypess, A.M. & Kahn, C.R. Cellular bioenergetics as a target for obesity therapy. Nat. Rev. Drug Discov. 9, 465–482 (2010).
Harper, J.A., Dickinson, K. & Brand, M.D. Mitochondrial uncoupling as a target for drug development for the treatment of obesity. Obes. Rev. 2, 255–265 (2001).
Harper, M.E., Green, K. & Brand, M.D. The efficiency of cellular energy transduction and its implications for obesity. Annu. Rev. Nutr. 28, 13–33 (2008).
Clapham, J.C. et al. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 406, 415–418 (2000).
Kopecky, J., Clarke, G., Enerback, S., Spiegelman, B. & Kozak, L.P. Expression of the mitochondrial uncoupling protein gene from the aP2 gene promoter prevents genetic obesity. J. Clin. Invest. 96, 2914–2923 (1995).
Li, B. et al. Skeletal muscle respiratory uncoupling prevents diet-induced obesity and insulin resistance in mice. Nat. Med. 6, 1115–1120 (2000).
Neschen, S. et al. Uncoupling protein 1 expression in murine skeletal muscle increases AMPK activation, glucose turnover, and insulin sensitivity in vivo. Physiol. Genomics 33, 333–340 (2008).
Ishigaki, Y. et al. Dissipating excess energy stored in the liver is a potential treatment strategy for diabetes associated with obesity. Diabetes 54, 322–332 (2005).
Choi, C.S. et al. Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance. J. Clin. Invest. 117, 1995–2003 (2007).
Amara, C.E. et al. Mild mitochondrial uncoupling impacts cellular aging in human muscles in vivo. Proc. Natl. Acad. Sci. USA 104, 1057–1062 (2007).
Maragos, W.F. & Korde, A.S. Mitochondrial uncoupling as a potential therapeutic target in acute central nervous system injury. J. Neurochem. 91, 257–262 (2004).
Mattiasson, G. et al. Uncoupling protein-2 prevents neuronal death and diminishes brain dysfunction after stroke and brain trauma. Nat. Med. 9, 1062–1068 (2003).
Parascandola, J. Dinitrophenol and bioenergetics: an historical perspective. Mol. Cell. Biochem. 5, 69–77 (1974).
Perry, R.J. et al. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. Cell Metab. 18, 740–748 (2013).
Frayha, G.J., Smyth, J.D., Gobert, J.G. & Savel, J. The mechanisms of action of antiprotozoal and anthelmintic drugs in man. Gen. Pharmacol. 28, 273–299 (1997).
Sheth, U.K. Mechanisms of anthelmintic action. Prog. Drug Res. 19, 147–157 (1975).
Weinbach, E.C. & Garbus, J. Mechanism of action of reagents that uncouple oxidative phosphorylation. Nature 221, 1016–1018 (1969).
Andrews, P., Thyssen, J. & Lorke, D. The biology and toxicology of molluscicides, Bayluscide. Pharmc. Ther. 19, 245–295 (1982).
Hecht, G. & Gloxhuber, C. Tolerance to 2′,5-dichloro-4-nitrosalicylanilide ethanolamine salt. Z. Tropenmed. Parasitol. 13, 1–8 (1962).
Owen, M.R., Doran, E. & Halestrap, A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348, 607–614 (2000).
Misbin, R.I. et al. Lactic acidosis in patients with diabetes treated with metformin. N. Engl. J. Med. 338, 265–266 (1998).
Kobayashi, K. et al. The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding. Metabolism 49, 22–31 (2000).
Samuel, V.T. et al. Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J. Biol. Chem. 279, 32345–32353 (2004).
Fryer, L.G., Parbu-Patel, A. & Carling, D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277, 25226–25232 (2002).
Inoki, K., Zhu, T. & Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577–590 (2003).
Zhou, G. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108, 1167–1174 (2001).
Chen, M. et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 48, 10267–10274 (2009).
Osada, T. et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res. 71, 4172–4182 (2011).
Ren, X. et al. Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway. ACS Med. Chem. Lett. 1, 454–459 (2010).
Fullerton, M.D. et al. Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat. Med. 19, 1649–1654 (2013).
Madiraju, A.K. et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510, 542–546 (2014).
Hollingworth, R.M. in Handbook of Pesticide Toxicology Vol. 2, 2nd edn. (ed. Krieger, R.) 1225–1247 (Academic Press, San Diego, California, 2001).
Swan, G.E. The pharmacology of halogenated salicylanilides and their anthelmintic use in animals. J. S. Afr. Vet. Assoc. 70, 61–70 (1999).
Frezza, C., Cipolat, S. & Scorrano, L. Organelle isolation: functional mitochondria from mouse liver, muscle and cultured fibroblasts. Nat. Protoc. 2, 287–295 (2007).
Trounce, I.A., Kim, Y.L., Jun, A.S. & Wallace, D.C. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol. 264, 484–509 (1996).
Muoio, D.M., Seefeld, K., Witters, L.A. & Coleman, R.A. AMP-activated kinase reciprocally regulates triacylglycerol synthesis and fatty acid oxidation in liver and muscle: evidence that sn-glycerol-3-phosphate acyltransferase is a novel target. Biochem. J. 338, 783–791 (1999).
Zhang, Y. et al. Adipose-specific deletion of autophagy-related gene 7 (atg7) in mice reveals a role in adipogenesis. Proc. Natl. Acad. Sci. USA 106, 19860–19865 (2009).
Prince, A., Zhang, Y., Croniger, C. & Puchowicz, M. Oxidative metabolism: glucose versus ketones. Adv. Exp. Med. Biol. 789, 323–328 (2013).
Chang, Y.-W. et al. Pharmacokinetics of anti–SARS-CoV agent niclosamide and its analogs in rats. J. Food Drug Anal. 14, 329–333 (2006).
Kim, H.J. et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53, 1060–1067 (2004).
Yu, C. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230–50236 (2002).